Breaking news

16:04Nov 26Reuters
CEO Video Presentation
07:00Nov 23Reuters
AstraZeneca unveils The Discovery Centre (DISC) in Cambridge
07:00Nov 19Reuters
Flexion Mobile bjuder in till företagspresentation och efterföljande frågestund
12:15Nov 18Reuters
Beowulf Investor Q&A
07:01Nov 18Reuters
New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention
07:04Nov 16Reuters
Two billion doses of AstraZeneca's COVID-19 vaccine supplied to countries across the world less than 12 months after first approval
07:02Nov 12Reuters
AstraZeneca PLC:s resultatrapport för de första nio månaderna och tredje kvartalet 2021
05:00Nov 09Reuters
Beowulf live investor Q&A
07:02Nov 05Reuters
AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021
07:01Nov 01Reuters
AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
06:02Okt 25Reuters
Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial at interim analysis
06:00Okt 22Reuters
Kallak Update
06:01Okt 15Reuters
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer
09:45Okt 12Reuters
NCC bygger tunnel för skyfall i Köpenhamn
08:59Okt 08Reuters
Eastnine hyr ut till norskt IT-bolag i Riga
06:01Okt 05Reuters
AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
16:00Okt 04Reuters
Wyld Networks: Första dag för handel i teckningsoptioner av serie TO3 fastställd till den 8 oktober 2021
15:00Sep 30Reuters
NCC säljer kontorsprojekt i Mölndal till Platzer
  • +
13:31Sep 30Reuters
IoT-teknikbolaget Wyld Networks förstärker styrelsen med Henrik Hedelius som ny ledamot
07:00Sep 28Reuters
Wyld Networks erhåller inköpsorder från den globala satellitoperatören Eutelsat S.A.
06:02Sep 23Reuters
AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity
06:01Sep 21Reuters
AstraZeneca to invest $360m in advanced manufacturing facility in Ireland
15:31Sep 18Reuters
Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
13:06Sep 18Reuters
Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
11:31Sep 18Reuters
Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
16:07Sep 17Reuters
Enhertu demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
11:31Sep 17Reuters
Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer
06:00Aug 31Reuters
Submission to the Swedish Government
06:00Aug 27Reuters
Unaudited Financial Results for the Period Ended 30 June 2021
06:06Aug 26Reuters
Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes